Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD

Dana J. Lukin,*,‡,§ Gabriela Funez-dePagnier,*‡,§ Svetlana Lima,§|| Daniel Lai,*‡,§ Lucia Duenas-Bianchi,*‡,§ Waseem Ahmed,*‡,§ Vinita Jacob,*‡,§ Robert Battat,*‡,§ Ellen Scherl,*‡,§ and Randy S. Longman*‡,§,*||

*Jill Roberts Center for Inflammatory Bowel Disease, New York, New York; ‡New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York; §Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, New York; and ||Jill Roberts Institute for Research in IBD, Weill Cornell Medicine, New York, New York

Although patients with inflammatory bowel disease (IBD) reported an increased frequency of gastrointestinal (GI) symptoms following infection,1,2 the durable impact of COVID-19 on IBD activity and the microbiome is not well defined. Our study aims were to compare clinical, endoscopic, and laboratory markers of disease activity and the fecal microbiome in IBD participants 6 months pre- and post-COVID-19.

Methods

Using an established longitudinal cohort, we identified 118 IBD patients with COVID-19 infection (Supplementary Table 1). Clinical characteristics and disease activity were assessed up to 6 months before COVID-19, during COVID-19 (defined as 1–30 days postinfection), and up to 6 months after. Active disease was defined by a Harvey Bradshaw Index >4, Mayo Score ≥2, Simple Endoscopic Score-Crohn’s Disease ≥2, or Mayo Endoscopic Score ≥1. 16S rRNA sequencing of V4 and V5 regions was analyzed using USEARCH and RDP database to generate OTU tables (Supplementary Methods).

Results

Although upper respiratory and new GI symptoms were common in patients with IBD (Supplementary Table 1), there were no significant changes in IBD clinical disease activity, endoscopic evaluation, or laboratory markers up to 7 months post-COVID-19 compared with the most recent evaluation up to 6 months before infection (Table 1). Active disease was present in 60% of the cohort before COVID-19 and 55% and 59% during and post-COVID-19, respectively.

Ten patients in our cohort reported a delay in medical therapy and 8 discontinued IBD medications during COVID-19; however, this subset and the 43 participants reporting GI symptoms during COVID-19 had no significant change in disease activity (Table 1). There were no differences in the need for corticosteroids, a change in medical therapy, or IBD-related surgery or hospitalization during or post-COVID-19 compared with the prior 6 months.

Preliminary studies in hospitalized patients with severe COVID-19 suggested the potential impact of infection on the microbiome.3 From a subset of 12 patients for whom fecal samples were available before COVID-19, 16S rRNA sequence was performed to assess the impact of infection on microbiome composition. Paired and unpaired analysis between pre- and post-COVID-19 samples revealed no significant difference in alpha diversity (Shannon index, Supplementary Figure 1A) or beta diversity (Bray-Curtis distance metric, Supplementary Figure 1B). Similar to previous results suggesting that IBD activity correlates with changes in the microbiome,4 principal coordinate analysis of Bray-Curtis distance metric revealed that the microbiome of mild disease (Harvey Bradshaw Index 5–7 or Mayo 3–5) was distinct from moderate disease (Harvey Bradshaw Index 8–16 or Mayo 6–10; Supplementary Figure 1C); however, there was no significant change comparing pre- and post-COVID-19 samples (Supplementary Figure 1D). In contrast, individual participants over time remained distinct (PERMANOVA, Subject × Time; P = .04; Supplementary Figure 1E). Similarly, principal coordinate analysis revealed no significant differences when stratified by those affected by COVID-19-associated diarrhea (Supplementary Figure 1F).

Discussion

With the increased frequency of new GI symptoms associated with COVID-19 in patients with IBD, there was initial concern that infection may lead to durable negative effects on IBD activity. This concern was further compounded by the need to delay or discontinue immunosuppressive therapy in IBD patients with active
COVID-19. Reassuringly, our data reveal no significant impact on disease activity during 6 months follow-up post-COVID-19. Although subjects profiled in this study were primarily managed as outpatients, most suffered from respiratory symptoms and about one-third with new-onset GI symptoms. Given the limited number of subjects in this study with severe COVID-19, it is important to follow additional cases of severe COVID-19 in patients with IBD and to assess the impact of long-haul symptoms. Encouragingly, these results indicate no significant need for IBD-related surgery or hospitalization.

Initial reports suggesting distinct changes in the microbiome of patients with severe COVID-19 raised the possibility that patients with IBD may be at higher risk for microbiome alterations, which could subsequently impact disease activity. Although our data show microbiome differences based on disease activity, we did not detect distinct changes in participants before and after COVID-19. Although validation in additional cohorts is required, our microbiome analysis reflects the first

### Table 1. Clinical, Endoscopic, and Laboratory Markers Pre-, During, and Post-COVID-19

| Variables                        | Pre-COVID -180 to -1 d | COVID 0 to +30 d | Post-COVID +31 to +210 d | P value Pre vs Post |
|----------------------------------|------------------------|------------------|--------------------------|---------------------|
| **Clinical DAI, Avg (n)**        |                        |                  |                          | .7397               |
| HBI                              | 4.7 (50)               | 4.7 (21)         | 4.9 (41)                 | .74                 |
| PMS                              | 3.0 (25)               | 4.8 (6)          | 2.1 (19)                 | .24                 |
| **Endoscopic DAI, Avg (n)**      |                        |                  |                          |                     |
| SES-CD                           | 7.2 (17)               | 7 (1)            | 8.9 (15)                 | .69                 |
| MES                              | 1.5 (9)                | 2 (1)            | 1.7 (11)                 | .70                 |
| **Biomarkers, Avg (n)**          |                        |                  |                          |                     |
| C-reactive protein               | 1.2 (83)               | 2.5 (15)         | 1.3 (56)                 | .18                 |
| ESR                              | 25 (63)                | 25 (14)          | 26 (44)                  | .95                 |
| Hemoglobin                       | 12.8 (84)              | 12.6 (26)        | 13.2 (60)                | .50                 |
| Fecal calprotectin               | 388 (44)               | 522 (12)         | 250 (40)                 | .20                 |
| Active disease, n (%)            | 49 (60)                | 16 (55)          | 38 (59)                  | .87                 |
| Delayed/discontinued             | 9 (69)                 | 5 (83)           | 4 (40)                   |                     |
| COVID-19 GI symptoms             | 20 (61)                | 8 (39)           | 20 (71)                  | .68                 |
| Need for surgery, n (%)          | 3 (2.8)                | 0 (0)            | 2 (1.8)                  | .99                 |
| Need for IBD hospitalization, n (%)| 6 (5.6)                | 2 (1.7)          | 7 (6.2)                  | > .99               |
| Medication change, n (%)         | 53 (50)                | 33 (28)          | 45 (40)                  | .14                 |
| Newly started                    | 42 (40)                | 14 (12)          | 36 (32)                  |                     |
| Steroid                          | 17 (16)                | 4 (3.4)          | 15 (13)                  |                     |
| Delayed                          | 2 (1.9)                | 10 (8.5)         | 5 (4.4)                  |                     |
| Discontinued                     | 20 (19)                | 8 (6.8)          | 15 (13)                  |                     |

**NOTE.** Unpaired Mann-Whitney and paired Wilcoxon revealed no significant differences between pre- and post-COVID-19 clinical, endoscopic, and laboratory values. Fisher exact test was used to compare differences in patient number with active disease, need for surgery, hospitalization, or medication change.

DAI, disease activity index; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HBI, Harvey Bradshaw Index; IBD, inflammatory bowel disease; MES, Mayo Endoscopic Score; PMS, partial Mayo score; SES-Cd, Simple Endoscopic Score-Crohn’s Disease.
longitudinal analysis of the fecal microbiome before and after COVID-19. Moreover, these findings are consistent with more recent reports suggesting that microbiome changes seen in patients with severe COVID-19 may reflect antibiotic use as part of hospital care rather than COVID-19 severity. Collectively, these data reveal no durable impact of COVID-19 on clinical IBD disease activity or microbiome composition and provide data supporting the current guidelines for continued IBD maintenance care during the pandemic.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2021.06.008.

References

1. Lukin DJ, Kumar A, Hajifathalian K, et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology 2020;159:1541–1544.
2. Brenner EJ, Ungaro RC, Geary RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020;159:481–491.
3. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020;159:944–955.
4. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15:382–392.
5. Rubin DT, Feuerstein JD, Wang AY, et al. AGA Clinical Practice Update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology 2020;159:350–357.
6. Britton GJ, Chen-Liaw A, Cossarini F, et al. SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19. medRxiv 2020.

Reprint requests
Address requests for reprints to: Randy S. Longman, MD, PhD, New York-Presbyterian Hospital/Weill Cornell Medical Center, Medicine, 413 East 69th Street, Box 190, New York, New York 10021. e-mail: ral2006@med.cornell.edu; fax: (212) 746-5077.

Conflicts of interest
The authors disclose the following: Dana J. Lukin has served as a consultant for AbbVie, Boehringer Ingelheim, Palatin, and Pfizer and received grant support from AbbVie, Janssen, Takeda, and the Kenneth Rainin Foundation. Randy S. Longman has served as a consultant for Pfizer and Bristol Myers Squibb. Ellen Scherl has served as a consultant and on the advisory board for AbbVie, Entera Health, Evidera, G1 Health Foundation, Janssen, Protagonist Therapeutics, Seres Health, Takeda Pharmaceuticals, and Bristol Myers Squibb, received grant support from Abbott (AbbVie), AstraZeneca, Janssen Research and Development, Pfizer, UCB, the UCSF–CCFA Clinical Research Alliance, Genentech, Seres Therapeutics, and Celgene Corporation, is a shareholder of Gilead, and has received nonbranded Speakers Bureau honoraria from G1Health Foundation and Janssen. The remaining authors disclose no conflicts.

Funding
JRC pilot award (Dana J. Lukin), National Institutes of Health NIDDK R01 114252, and Kenneth Rainin Foundation (Randy S. Longman).
Supplementary Methods

IBD clinical disease activity (Harvey Bradshaw Index, partial Mayo score), endoscopic score, and laboratory markers (erythrocyte sedimentation rate, C-reactive protein, hemoglobin, fecal calprotectin) were assessed up to 6 months before COVID-19, during COVID-19 (defined as 1–30 days postinfection), and up to 6 months after. Values were compared using unpaired Mann-Whitney or paired Wilcoxon tests. The need for corticosteroids, a change in medical therapy, or IBD-related surgery/hospitalization during or post-COVID-19 was compared with the preceding 6 months. Values were compared using Fisher exact test. In a subset of 12 patients, 16S rRNA sequencing was performed as previously described and data were rarified at 10,000 reads per sample. Briefly, the 16S rRNA gene V4 and V5 regions were amplified as previously described (https://earthmicrobiome.org). Amplicons were then sequenced in an Illumina MiSeq platform using the 2 × 250 bp paired-end protocol. Read pairs were processed using USEARCH1 and the RDP database2 to generate a rarefied OTU table. Alpha and beta diversity analyses were then performed at the OTU-level. Microbiome analysis was performed in R studio (Boston, MA). Alpha and beta diversity was calculated using R package "phyloseq,"3 whereas plots were constructed in "ggplot2." Beta divergence based on Bray-Curtis dissimilarity was calculated using microbiome package in R studio. Bray-Curtis distance metric was used to evaluate microbiome composition before and after COVID-19 and Monte Carlo permutation test (PERMANOVA) was used to assess differences between centroids shown in the principal coordinate plots.

References

1. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010;26:2460–2461.
2. Cole JR, Wang Q, Fish JA, et al. Ribosomal Database Project: data and tools for high throughput rRNA analysis. Nucleic Acids Res 2014;42:D633–642.
3. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8:e61217.
Supplementary Figure 1.

IBD fecal microbiome before and after COVID-19. (A, B) Shannon index and Bray-Curtis divergence is shown for paired 16S rRNA microbiome samples from 12 participants pre- and post-COVID-19. (C–F) Principal coordinate analysis using Bray-Curtis distance metric showing the microbiome composition stratified by (C) IBD disease activity, (D) pre- or post-COVID-19, (E) individual participants (color coded), or (F) new diarrhea symptom. *P* value determined by PERMANOVA is shown.
### Supplementary Table 1. Clinical Characteristics and Comorbidities of COVID-19 IBD Cohort

| Variable                                      | All IBD (n = 118) |
|------------------------------------------------|------------------|
| Age, y, mean (SD)                              | 42.1 (16)        |
| Sex, n (%)                                     |                  |
| Female                                         | 63 (54)          |
| Male                                           | 54 (46)          |
| IBD type                                       |                  |
| Crohn’s disease                                | 73 (62)          |
| Ulcerative colitis                             | 40 (34)          |
| Other colitis                                  | 5 (4.2)          |
| Body mass index, kg/m² average (SD)            | 27 (6.8)         |
| Comorbidities, n (%)                           |                  |
| Obesity                                        | 30 (25)          |
| Former smoker                                  | 23 (20)          |
| Current smoker                                 | 2 (1.7)          |
| Diabetes                                       | 5 (4.3)          |
| CAD                                           | 2 (1.7)          |
| Heart failure                                  | 1 (0.9)          |
| Hypertension                                   | 20 (17)          |
| Asthma                                         | 8 (6.9)          |
| COPD                                           | 0 (0)            |
| Cirrhosis                                      | 1 (0.9)          |
| Chronic kidney disease                         | 1 (0.9)          |
| Current medications, n (%)                    |                  |
| Any biologic                                   | 65 (55)          |
| Anti-TNF                                       | 23 (20)          |
| Vedolizumab                                    | 22 (19)          |
| Ustekinumab                                    | 20 (17)          |
| JAK inhibitors                                 | 6 (5.1)          |
| Immunomodulator                                | 4 (3.4)          |
| Steroids                                       | 19 (16)          |
| Prednisone                                     | 8 (6.8)          |
| Budesonide                                     | 11 (9.3)         |
| Mesalamines                                    |                  |
| Oral                                           | 40 (34)          |
| Rectal                                         | 25 (21)          |
| Hypertension medications                      | 17 (15)          |
| ACE-ARB medications                            | 7 (6.0)          |
| NSAIDS                                         | 4 (3.4)          |
| COVID-19 symptoms, n (%)                       |                  |
| Upper respiratory                              | 97 (87)          |
| Gastrointestinal                               | 43 (39)          |
| COVID treatment, n (%)                         |                  |
| Steroids                                       | 6 (5.4)          |
| Azithromycin                                   | 20 (18)          |
| Hydroxychloroquine                             | 12 (11)          |
| Lopinavir/ritonavir                            | 0 (0)            |
| Tocilizumab                                    | 1 (0.9)          |
| Remdesivir                                     | 1 (0.9)          |
| Other antibiotics                              | 2 (1.9)          |
| COVID outcomes, n (%)                          |                  |
| ED visit                                       | 18 (15)          |
| Hospitalization                                | 8 (6.8)          |
| Ventilation                                    | 1 (0.9)          |
| ICU                                            | 1 (0.9)          |
| Death                                          | 0 (0)            |

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ED, emergency department; IBD, inflammatory bowel disease; ICU, intensive care unit; NSAIDS, nonsteroidal anti-inflammatory drugs; SD, standard deviation; TNF, tumor necrosis factor.